The Lao Government has opened a donation channel for all those looking to contribute financially to the fight against the outbreak of COVID-19.
BLUETTI at IFA Berlin 2025: Empowering a Greener Tomorrow with Clean Energy
BERLIN, Sept. 7, 2025 /PRNewswire/ — At IFA Berlin, BLUETTI, a leading provider of energy storage solutions, unveils three breakthroughs: the Pioneer Na, the world’s first sodium-ion portable power station; the RVSolar integrated off-grid solution; and FridgePower slim backup power. These innovations, alongside BLUETTI’s robust lineups, advance the company’s dedication to a sustainable future.
“A green future rests on our everyday choices,” said Allen Huang, Global Vice President of BLUETTI. “BLUETTI innovates to blend clean energy into daily life — at home, on the road, or in the most demanding environments.”
Reliable Energy for Outdoors
The Pioneer Na marks a new era in portable power with sodium-ion technology. Designed for extreme climates, it delivers 1,500W output even at -25°C (-13°F) and safely recharges at -15°C (5°F). Its 900Wh sodium-ion battery enables resource-abundant energy with over 10-year reliability. The Elite series, including Elite 200 V2, Elite 100 V2, and Elite 30 V2 balances portability and capacity for home backup, outdoor adventures, and RV life. For everyday power challenges, the Premium series is built strong and affordable.
Self-Sufficient Power During RV Travel
RVSolar System, 5 kVA and 48 V, brings off-grid RV power to life with a 30‑minute, screw-and-play installation. Featuring the RV5 5‑in‑1 hub, flexible solar panels, and full third-party compatibility, it charges via solar, grid, generator, or alternator for uninterrupted adventure-ready energy.
Stay Powered Wherever Off the Grid
The Apex 300, paired with smart accessories, creates a flexible power ecosystem for cabins, workshops, and home offices. With 3,840W output, expandable capacity up to 16.5kWh, and efficient charging via SolarX 4K, it delivers grid-like reliability at a low initial cost.
Survive Outages and High Bills
FridgePower is just 75 mm thin, about the width of a smartphone, and fits flat, vertical, or wall-mounted. It also offers hands-free voice control via Google Home and Alexa. For whole-home energy, the modular EP2000 ESS scales to 20 kW/51.6 kWh, integrates with PV for up to 30 kW solar, and helps households maximize self-consumption and reduce bills.
Visit BLUETTI at IFA Berlin 2025
Date: September 5–9, 2025
Booth: Hall 2.2, Stand 213, Germany.
About BLUETTI
As a technology pioneer in clean energy, BLUETTI delivers affordable energy storage for homes and outdoor lifestyles. Through its LAAF (Lighting An African Family) initiative, it has supported over 60,000 residents in off-grid African communities.
CATL Launches Shenxing Pro, Europe’s Optimal Solution for E-Mobility at IAA Mobility 2025
MUNICH, Sept. 7, 2025 /PRNewswire/ — At CATL Open Day, the company unveiled Shenxing Pro, the world’s first lithium iron phosphate (LFP) battery that can achieve sustained high voltage supply, maintained power, no fire, and no smoke after thermal runaway. Designed to meet Europe’s e-mobility needs, Shenxing Pro sets new benchmarks in safety, lifespan, range, and superfast-charging, positioning it as the optimal solution for the Europe’s rapidly expanding electric vehicle (EV) market.
Addressing Europe’s EV Market Challenges
EV adoption in Europe is accelerating at pace. According to SNE and MarkLines, Europe’s EV penetration rate rose from 23% to 26% in the first half of 2025, with projections suggesting it will hit 29% by year-end. The International Energy Agency (IEA) expects EV sales across Europe to reach 4 million units this year, up from 3.2 million in 2024.
However, persistent consumer concerns remain. McKinsey’s 2025 Consumer Mobility Pulse Survey highlights key barriers: high costs, battery lifespan, range limitations, charging infrastructure gaps and battery safety. Shenxing Pro directly addresses these barriers, delivering performance and safety tailored to Europe’s diverse driving needs.
Revolutionizing E-Mobility with Breakthrough Battery Technology
Shenxing Pro, equipped with CATL’s proprietary NP 3.0 Technology, represents a leap forward in battery innovation. With comprehensive advancements in levels of chemistry, mechanical structure, system and control, it offers two variants:
Shenxing Pro Super Long Life & Long Range Battery: The world’s first LFP battery to deliver a 758 km WLTP range and a record-breaking 12-year / 1,000,000 km lifespan, driving breakthroughs in battery lifespan and range performance. With 9% degradation after the first 200,000 km, it is perfectly tailored to support Europe’s leasing markets.
Shenxing Pro Super-Fast Charging Battery: It charges 478 km WLTP range in just 10 minutes—equivalent to 0.8 km per second—establishing it as the leading superfast-charging LFP battery in Europe. Delivering 830 kW with 0-100 km/h in just 2.5 seconds even at 20% state of charge (SOC), it achieves thrilling performance and enduring reliability across varied conditions. It maintains exceptional performance in extreme cold, achieving 410 km of range in 20 minutes at –20°C. Backed by up to a 10-year / 240,000 km warranty, it redefines the standards of superfast-charging resilience.
Both variants leverage CATL’s proprietary NP 3.0 technology, the pinnacle of CATL’s seven-year evolution of No Propagation (NP) safety innovations. Recognized as the world’s best-in-class safety performance, NP 3.0 enables sustained high-voltage supply for over an hour post-thermal runaway, maintains the vehicle’s speed, allowing drivers to calmly navigate their vehicles away from danger zones and ensures no flames and no smoke. As L3 and L4 autonomous driving shifts more accident responsibility to vehicle systems, Shenxing Pro ensures uninterrupted power and system continuity in emergencies, meeting the elevated safety and risk response demands of this era.
Shenxing Pro incorporates CATL’s innovative Wave cells, which feature a raised shoulder design and space-sharing technology. This is the world’s first battery that allows cooling systems and fixation to be applied from any direction, as opposed to only having limited choice before. It achieves omnidirectional vibration suppression, boosting battery pack stiffness by 25% and doubling durability. Shenxing Pro breaks traditional Cell-to-Body (CTB) limitations through its cell design, achieving a remarkable 76% pack volume efficiency. By combining these advancements, Shenxing Pro redefines electric mobility in Europe, delivering unprecedented safety, extended range, exceptional lifespan and superfast-charging performance.
“Shenxing Pro seamlessly fuses world-class safety standards with mobility needs, delivering a safer, more efficient, and carefree experience for every journey,” said Dr. Lingbo Zhu, CTO of CATL’s International Business Unit. “With uncompromised range, charging, and durability, Shenxing Pro is the ultimate solution for electric mobility in Europe.”
Strengthening Europe’s E–Mobility Ecosystem
CATL has steadily deepened its European footprint, evolving from exporting batteries “to Europe” to building “in Europe, for Europe.” With over €11 billion investment in European operations, CATL has created thousands of jobs and fostered local talent through partnerships with universities and vocational institutions.
Collaborating with over 200 carmakers worldwide, including long-standing European partners and over 1,000 European suppliers, CATL advances innovation by collaboratively integrating state-of-the-art battery technologies into electric vehicles.
“With cutting-edge technologies, diverse global operations, proven manufacturing expertise, and a mindset of open collaboration, CATL is committed to being a reliable partner to the European automotive industry. By combining our advanced capabilities with Europe’s decades-long automotive expertise, we aim to go beyond ‘in Europe, for Europe‘ and ultimately ‘of Europe,’ building a greener, smarter and more thriving EV ecosystem that spans from material production, battery making, remanufacturing and recycling to accelerate the region’s energy transition,” said Tan Libin, CCO and SVP of global business of CATL.
A Shared Vision for a Sustainable Mobility
With the launch of Shenxing Pro, CATL reinforces its long commitment to Europe’s sustainable mobility future. Drawing on global expertise – powering over 20 million electric vehicles across more than 300 billion kilometres – CATL is driving innovation in safety, performance, and sustainability. By deepening its European presence, CATL aims to create a future-ready ecosystem, partnering with the region’s automotive partners to deliver electrification that is safe, reliable, and sustainable.
BLUETTI Unveils Pioneer Na, RVSolar System and FridgePower at IFA 2025
BERLIN, Sept. 7, 2025 /PRNewswire/ — BLUETTI, a global leader in clean energy storage, unveiled three groundbreaking products at IFA 2025: the Pioneer Na (Sodium), RVSolar System, and FridgePower. The Pioneer Na and RVSolar System have already won the IFA Tech for Good Social Impact Award for innovation and sustainability.
Pioneer Na: World’s First Sodium-Ion Portable Power Station
The Pioneer Na debuts sodium-ion technology for portable storage, performing reliably even in extreme cold down to -25 °C (-13 °F). With dual AC + PV charging, it recharges from 0–80% in 35 minutes. Delivering 1,500W output (2,250W in Power Lifting mode) and a 900Wh sodium-ion battery, it is cobalt- and lithium-free, marking a breakthrough in sustainable storage. Ideal for cold regions and polar expeditions, the Pioneer Na will be available worldwide from October 15, 2025.
RVSolar System: Off-Grid Living Made Easy
RVSolar System is BLUETTI’s first fully integrated solution for RVs, boats, and cabins, built on a powerful 5-in-1 hub for centralized energy control. Its modular design allows DIY installation in 30 minutes, with no complex wiring. Compatible with third-party batteries and solar panels via CAN protocol, it supports flexible, cost-effective expansion. With 5 kVA/6,000 W output powering 99% of appliances, expandable to 122 kWh for a week’s independence, it offers four charging options, 90-minute recharge, and lower than 20 ms UPS time. Certified to UL and RV-C standards, the RVSolar System launches globally from September 30, 2025.
FridgePower: Ultra-Slim Smart Backup Anywhere
FridgePower is just 75 mm thin, about the width of a smartphone, and fits effortlessly with flat, vertical, or wall-mounted installation. With Google Home and Amazon Alexa compatibility, it offers hands-free voice control. Featuring a 2,016 Wh capacity and 1,800 W output, expandable up to 8,064 Wh with three BlueCell 200 modules, it powers fridges, appliances, and off-grid equipments. With an ultra-low self-consumption, 87% lower than competing products, it ensures efficiency while intelligent monitoring forecasts demand, switches seamlessly, and issues alerts. FridgePower will be available worldwide from November 4, 2025.
Meet BLUETTI at IFA 2025
September 5–9, Booth H2.2-213, Messe Berlin
About BLUETTI
As a technology pioneer in clean energy, BLUETTI delivers affordable energy storage for homes and outdoor lifestyles. Through its LAAF (Lighting An African Family) initiative, it has supported over 60,000 residents in off-grid African communities.
Federation of Hong Kong Changzhou Youth Officially Established, Uniting Youth Power to Open a New Chapter in Changzhou-Hong Kong Cooperation
HONG KONG, Sept. 7, 2025 /PRNewswire/ — On the afternoon of September 6, the inauguration ceremony of the Federation of Hong Kong Changzhou Youth was solemnly held in Hong Kong. The Honourable Tang Ping-keung, Secretary for Security of the Hong Kong SAR; the Honourable Henry Tang Ying-yen, Standing Committee Member of the National Committee of the Chinese People’s Political Consultative Conference (CPPCC) and Founding President of the Federation of HK Jiangsu Community Organisations; Mr. Yu Xuejie, Deputy Director of the Community Liaison Department of the Liaison Office of the Central People’s Government in the Hong Kong SAR; Mr. Zhang Guolai, Second-level Inspector of its Youth Work Department; the Honourable Yiu Mau Lung , Member of the CPPCC National Committee and President of the Federation of HK Jiangsu Community Organisations; Ms. Yang Fen, Member of the Standing Committee of the Changzhou Municipal Party Committee, Director of the United Front Work Department, and President of the Changzhou Overseas Friendship Association; and the Honourable Dr. Ko Wing-man, Standing Committee Member of the CPPCC National Committee and Chairman of the TCM All-sector Hong Kong Centre, joined over 200 representatives from across Hong Kong society to witness this landmark occasion, which strengthens Changzhou–Hong Kong ties and empowers youth development.
In his address, Secretary Tang Ping-keung noted that the establishment of the Federation provides an important platform for Changzhou youth in Hong Kong. He encouraged young people to actively integrate into Hong Kong society, play a proactive role in supporting Hong Kong’s prosperity and stability, and contribute their youthful energy to the country’s broader development.
In his remarks, Henry Tang reflected on Changzhou’s rich cultural heritage and dynamic development. He noted that Hong Kong, as a “super-connector,” holds unique advantages and expressed hope that young people would leverage this role to advance Jiangsu–Hong Kong cooperation from “economic and trade connectivity” to “people-to-people bonds,” bringing greater warmth and depth to ties between the two regions.
In her address, Yang Fen expressed hope that the Federation of Hong Kong Changzhou Youth would act as a bridge, facilitating deeper integration between Changzhou’s industrial strengths and Hong Kong’s international resources through various exchange activities. She encouraged young people to seize the opportunities of the era, uphold a spirit of patriotism and devotion to Hong Kong, continue innovating in their respective fields, and contribute to Hong Kong’s long-term stability and to the nation’s prosperity.
Mr. CHIU Lon Ronald, Chairman of CSC Group, serves as the inaugural president of the Federation of Hong Kong Changzhou Youth. He said the Federation would adhere to the principle of “patriotism, love for Hong Kong and the hometown, and a sense of commitment, solidarity and responsibility,” focus on cutting-edge fields such as AI and fintech, provide platforms for exchange and cooperation between Changzhou and Hong Kong youth, and facilitate the joint development of young people from both regions.
On the same day, a panel discussion themed “AI and FinTech: Empowering New Opportunities for Jiangsu-Hong Kong Youth Development” was held. Mr. Witman Hung, Founder of Shenzhen ZebraS Technology Acceleration Platform, Mr. Lu Haitian, Director of Mainland Development at The Hong Kong Polytechnic University, and other experts held in-depth discussions with youth representatives on topics such as Jiangsu–Hong Kong industrial collaboration, technological innovation, and youth development pathways, exploring new directions for cooperation between young people from both regions.
The establishment of the Federation of Hong Kong Changzhou Youth has not only created a “warm home” for Changzhou youth in Hong Kong to foster bonds of hometown affinity and pursue shared development, but has also marked a new stage in youth exchange and cooperation between Changzhou and Hong Kong. Looking ahead, the Federation will continue to act as a bridge, bringing together the wisdom and energy of young people to contribute new chapters to the deep integration of Jiangsu and Hong Kong and to the broader goals of national development.
Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332
- The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332
- In the North American patients, the OS HR was 0.70
- The HARMONi trial has already demonstrated clinically meaningful and statistically significant progression-free survival (PFS) outcomes
- In the HARMONi trial, clinical endpoint benefits, including OS and PFS, were consistent across Western and Asian patient populations, and these results were also in alignment with the clinical data from the HARMONi-A trial conducted in China
HONG KONG, Sept. 7, 2025 /PRNewswire/ — Akeso, Inc. (HKEX: 9926.HK) is pleased to share today that its global partner, Summit Therapeutics Inc. (NASDAQ: SMMT), announced the updated overall survival (OS) results from the global Phase III HARMONi clinical trial of ivonescimab, a novel PD-1/VEGF bispecific antibody, at the Presidential Symposium in the 2025 World Conference on Lung Cancer (WCLC).
Longer-term follow-up of western patients showed improving, favorable trend in OS, yielding a hazard ratio (HR) of 0.78 and a nominal p-value of 0.0332.
Meanwhile, Akeso recently announced that the HARMONi-A study conducted in China has also recently reached the OS clinical endpoint, achieving clinically meaningful and statistically significant OS benefit. The OS data from this study will be presented at upcoming academic conferences.
The results from the first international multi-center Phase III HARMONi study of ivonescimab, along with those from the Phase III HARMONi-A study conducted in China, demonstrated consistent and robust clinical efficacy in both progression-free survival (PFS) and OS. These findings provide strong evidence that ivonescimab not only offers significant advantages in terms of rapid onset of action and effective disease control in cancer treatments but also provide survival benefits to patients. The data further support ivonescimab’s consistent efficacy and safety across diverse global populations, including both international and Chinese cohorts, reinforcing its potential for broad therapeutic benefit for cancer patients worldwide.
Approximately 38% of patients were recruited from western countries.
The trial results were presented by Jonathan Goldman, MD, Professor of Medicine at UCLA in the Hematology/Oncology Division, UCLA Director of Clinical Trials in Thoracic Oncology, Associate Director of Early Drug Development, and Chair of University of California Lung Cancer Consortium.
Clinically Meaningful Efficacy
As previously disclosed, ivonescimab in combination with chemotherapy showed a positive trend in OS in the primary analysis without achieving a statistically significant benefit with a hazard ratio of 0.79 (95% CI: 0.62 – 1.01; p=0.057). The statistical analysis plan for the study required a p-value of 0.0448 in order to achieve statistical significance at the time of the primary analysis of overall survival. Median overall survival was 16.8 months for those patients administered ivonescimab plus chemotherapy vs. 14.0 months for those receiving placebo plus chemotherapy. It was noted at the time of the primary analysis that the median follow-up time for western patients was 9.2 months and less than the median overall survival at the time of the primary analysis, and these patients may continue to be followed for long-term outcomes.
In September 2025, an additional analysis was performed, whereby the western patients were followed to increase their time on study (Asian patients were locked at the time of the primary analysis). In this analysis that included longer-term follow-up of western patients (median follow-up time of western patients of 13.7 months), a hazard ratio consistent with the primary analysis was observed with an improved nominal p-value (HR=0.78; 95% CI: 0.62 – 0.98; nominal p=0.0332). Median OS for this analysis remained the same in both arms from the primary analysis. Median OS in western patients receiving ivonescimab was 17.0 months compared to 14.0 months for those receiving placebo (HR=0.84); median OS in North American patients, specifically, had not yet been reached in the ivonescimab arm compared to 14.0 months in the placebo arm (HR=0.70). The hazard ratios for western patients in totality, as well as patients from the North American and European regions individually, improved from the primary OS analysis to the analysis with longer-term follow-up of western patients. Consistent benefit was observed across pre-defined subgroups.
As previously disclosed at the prespecified primary data analysis for PFS, ivonescimab in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement with a hazard ratio of 0.52 (95% CI: 0.41 – 0.66; p<0.00001). PFS was measured by blinded independent central radiology review committee (BICR) compared to placebo in combination with chemotherapy. Median PFS for ivonescimab vs. placebo plus chemotherapy was 6.8 months vs. 4.4 months, respectively. The PFS analysis was event driven and was conducted with 345 patients enrolled. There was a consistent observed benefit across pre-defined subgroups.
In a longer-term follow-up of PFS, which included all western patients and at least six months of follow-up time for all patients, ivonescimab plus chemotherapy demonstrated a consistent, clinically meaningful improvement in PFS with an observed HR of 0.57 (95% CI: 0.46 – 0.71). With the longer-term follow-up analysis, a consistent benefit in western vs. Asian patients was observed, as well as in patients with tumors with either PD-L1 positive or negative expression. This longer-term follow-up analysis of PFS was performed at the time of the primary OS analysis.
Overall response rates were higher in the ivonescimab arm (45%) vs. the placebo arm (34%); median duration of response was longer in those patients administered ivonescimab plus chemotherapy (7.6 months) compared to those receiving placebo and chemotherapy (4.2 months)
Ivonescimab demonstrated a favorable safety and tolerability profile with no new safety signals identified. The safety results from the HARMONi study were consistent with those observed in the HARMONi-A trial.
Ivonescimab has shown positive results in the HARMONi-2 trial, a randomized, double-blind, head-to-head Phase III study against pembrolizumab monotherapy, which led to its approval for first-line treatment of PD-L1-positive NSCLC (its second approved indication). Besides that, ivonescimab plus chemotherapy has now also demonstrated significant positive outcomes in another head-to-head Phase III study against tislelizumab plus chemotherapy in first-line squamous NSCLC. This clinical outcome demonstrates that ivonescimab shows significant clinical breakthroughs, whether compared to PD-1 monotherapy, or compared to PD-1 in combination with chemotherapy (the optimal standard of care for many cancer treatments), or compared to VEGF-related therapies in the area of anti-angiogenesis. This highlights the remarkable capability of ivonescimab to make leapfrog advancements in cancer treatment.
Ivonescimab continues to validate its clinically meaningful profile and potential with a strategically expanded development program targeting key immuno-oncology settings:
Phase III trials for Lung cancer (8 registrational/Phase III trials, 4 already met primary endpoints):
- First-line NSCLC, squamous and non-squamous (versus pembrolizumab + chemotherapy; global trial)
- First-line squamous NSCLC (versus tislelizumab + chemotherapy)
- NSCLC after progression on EGFR-TKI therapy (HARMONi-A and HARMONi studies)
- First-line PD-L1-positive NSCLC (versus pembrolizumab monotherapy)
- First-line PD-L1-high expressing NSCLC (versus pembrolizumab)
- IO-resistant NSCLC
- Consolidation therapy for limited-stage small cell lung cancer (LS-SCLC) without progression after concurrent chemoradiotherapy (cCRT)
Phase III trials for core immuno-oncology indications (first-line therapy):
- First-line biliary tract cancer (versus durvalumab + chemotherapy)
- First-line PD-L1-positive head and neck squamous cell carcinoma (HNSCC) in combination with ligufalimab (anti-CD47) versus pembrolizumab
Phase III trials for cold tumors and more:
- First-line triple-negative breast cancer (TNBC)
- First-line MSS/pMMR colorectal cancer (representing about 95% of CRC cases)
- First-line pancreatic cancer
- Additional global Phase III trials are in advanced stages of planning
An extensive clinical foundation includes over 20 Phase II studies across more than 10 additional tumor types, generating compelling efficacy and safety data to enable rapid transition to further registrational studies worldwide.
Ivonescimab uniquely targets both PD-1 and VEGF, producing a synergistic anti-tumor effect. This dual mechanism not only combines the benefits of PD-1 and VEGF inhibition but also overcomes the efficacy and safety limitations of each target alone, resulting in pronounced clinical benefits. These advantages have been confirmed across multiple Phase III trials and real-world use, rapidly establishing ivonescimab as a next-generation leader in immunotherapy and anti-angiogenic therapy.
Akeso is implementing a dual-path strategy to maximize the value of ivonescimab world wide: accelerating domestic commercialization and label expansion in China, while simultaneously advancing global development in partnership with Summit Therapeutics.
Forward-Looking Statement of Akeso, Inc.
This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.
For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.
Global South media, think tank forum opens in southwest China’s Yunnan
KUNMING, China, Sept. 7, 2025 /PRNewswire/ — The 2025 Global South Media and Think Tank Forum opened Saturday in Kunming, capital of southwest China’s Yunnan Province.
Fu Hua, president of Xinhua News Agency, addresses the opening ceremony of the 2025 Global South Media and Think Tank Forum in Kunming, southwest China’s Yunnan Province, Sept. 6, 2025. Some 500 journalists, scholars, government officials and entrepreneurs from 110 countries or international and regional organizations convened here for the 2025 Global South Media and Think Tank Forum. (Xinhua/Gao Jie)
The event has gathered around 500 participants from more than 260 media outlets, think tanks, government agencies and international organizations across 110 countries and regions.
The Global Governance Initiative, recently proposed by China, provides important guidance for the Global South to jointly reform the global governance system, said Hu Heping, deputy head of the Publicity Department of the Communist Party of China (CPC) Central Committee, when addressing the opening ceremony.
Hu expressed optimism that the forum would enhance communication and exchanges among media and think tanks, helping Global South countries strengthen cooperation amid global transformations and jointly build a better future.
Fu Hua, president of Xinhua News Agency, said in his address that as China’s national news agency and a global news organization, Xinhua stands ready to work with all parties to tell the stories of how Global South leaders guide and promote the building of a community with a shared future for humanity.
He stressed the importance of enhancing research and dissemination of important ideas, and leveraging multilateral exchange mechanisms, to tap into the full potential of discourse, and mobilize driving forces for the development and prosperity of the Global South.
Media and think tanks of the Global South should explore cooperative potential in areas such as strengthening information sharing, promoting personnel exchanges, and telling the stories of the Global South effectively, said Khamphan Pheuyavong, member of the Secretariat of the Lao People’s Revolutionary Party (LPRP) Central Committee, head of the Propaganda and Training Commission of the LPRP Central Committee, and president of the Theory Council of the LPRP Central Committee, at the opening ceremony.
In a video address to the opening ceremony, Melissa Fleming, the United Nations under-secretary-general for global communications, called for joint efforts to enhance global sustainability and intercultural exchanges, restore balance to the global information ecosystem, and incorporate integrity into the online public sphere.
The forum, running through next Tuesday, is co-hosted by Xinhua News Agency, the CPC Yunnan Provincial Committee and the People’s Government of Yunnan Province.
Dreame’s innovations earned multiple honors at IFA Innovation Awards 2025
BERLIN, Sept. 7, 2025 /PRNewswire/ — At IFA 2025, Dreame Technology showcased a comprehensive range of smart home solutions designed to empower users to live their dream life. From the world’s first stair-climbing robot vacuum to the DZ60 Pro Fully-integrated Dishwasher, the OZ60 Pro Built-in Steam Oven, and the Aura Mini LED 4K TV S100, each product exemplifies Dreame’s industry-leading technological strength and spirit of innovation.
Dreame Cyber X
Cyber X represents a leap forward in robotic engineering: a vacuum system designed to clean multiple floors autonomously, solving one of the most persistent household challenges. At its core, Cyber X consists of three key components: the robotic vacuum, the Bionic QuadTrack™ stair-climbing system, and the base station. The QuadTrack™ system is the centerpiece, capable of climbing stairs up to 25 cm in height at 0.2 m/s, dynamically adapting to varying step widths and geometries, making stair climbing smooth, fast, and safe.
When Cyber X needs to move from one floor to another, the vacuum docks onto the QuadTrack™ system, which functions like a mini elevator for the vacuum. The system carries the vacuum to the next level, then automatically releases it to begin cleaning. After completing its tasks, the vacuum uses the same process to return or continue cleaning, eliminating any need for manual lifting.
Aqua Series
During IFA 2025, Dreame is introducing its all-new form of robot vacuum — the Aqua Series. Just like the flagship X Series with dual-disc mops, the Aqua Series will continue to evolve with each generation, establishing itself as one of Dreame’s dual-flagship series. The Aqua10 Pro Track brings advanced mopping technology to life with TrackSync™ Constant Hot Water Mopping, Dreame’s first fresh water cleaning system. Continuous hot water combined with automated solution refilling keeps floors pristine while efficiently navigating obstacles. Designed specifically for hard floor users, it features a broader contact area with stronger downward pressure, tackling tough, stuck-on stains and deep floor crevices with ease.
Matrix10 Ultra
The Matrix10 Ultra features the industry-first Multi-Mop Switching Dock and Three-Solution Compartment, automatically adapting to different areas with the right mop pads. It holds up to three mop types, switching based on room type or cleaning needs: nylon-bristled scrubbing pads for grease in the kitchen, sponge water-locking pads for bathrooms, and thermal mop pads for other rooms, maintaining consistent temperature for enhanced cleaning.
The Three-Solution Compartment delivers tailored solutions for pet odors, wood floor care, and general cleaning, ensuring each area is treated appropriately.
H15 Pro FoamWash
As a key tool for deep home cleaning, Dreame’s H15 Pro FoamWash introduces pet-friendly FoamWash Technology, creating a new cleaning revolution for pet households. In addition to Dreame’s signature features such as 180° Lie-Flat Reach under low furniture, Immersive 100°C Hot Water Self-Cleaning, and upgraded 23,000Pa suction, and the H15 Pro FoamWash features targeted foam application, spraying specialized pet-friendly cleaning foam directly onto stains to dissolve dirt and neutralize lingering odors such as pet waste.
Miracle Pro
The first “Fragrant Mist × Dual-Wavelength Red Light × AI Smart Mode” triple hair-care system. Micron-level atomized essence (containing sturgeon caviar, white truffle extract, and hydrolyzed keratin) reaches deep into the hair core, nourishing hair while drying it.
Dual-Wavelength Red Light (1064nm deep, 633nm surface) stimulates scalp blood flow, with 600 million negative ions strengthening hair health.
Smart AI thermal system control adjusts airflow temperature and speed in real-time for optimal heat control.
Kitchen Innovations: DZ60 Pro & OZ60 Pro
Dreame also expanded into kitchen appliances with two flagship launches:
- DZ60 Pro Fully-integrated Dishwasher: Certified with Singapore’s highest 4-Tick WELS rating, it features a 360° HydraFlow Wash System, app connectivity for 24-hour scheduling, and a seamless built-in design.
- OZ60 Pro Built-in Steam Oven: Combining steam, bake, and air fry functions, it delivers versatility with 1600W steam injection, multi-mode cooking, and precise PID heat control for professional results at home.
Award-Winning Excellence
Dreame’s innovations earned multiple honors at IFA Innovation Awards 2025:
- Matrix10 Ultra — Best in Smart Home
- DZ60 Pro Fully-integrated Dishwasher — Best in Home Appliances
- Miracle Pro — Best in Beauty & Personal Care
- H15 Pro FoamWash — Honoree
These award-winning products have officially launched in Southeast Asia, including Singapore and Malaysia, and are now available through Dreame’s official website.
About Dreame Technology
Established in 2017, Dreame Technology is an innovative consumer product company that focuses on smart home cleaning appliances with the vision to empower lives through technology.
For more information, please visit: https://global.dreametech.com/
GAC Teams Up with SKAI ISYOURGOD for “Tyrannosaurus” Remix of Blueprint Supreme, AION V Breaks the Beat!
GUANGZHOU, China, Sept. 7, 2025 /PRNewswire/ — Recently, GAC joined hands with world-renowned rapper SKAI ISYOURGOD—famed for his viral hits Grand Plans and Fortune All Around—along with the highly popular Buqicrew, celebrated for their unique dance style, to create a special “Tyrannosaurus” edition of Grand Plans for its new hardcore intelligent-driving SUV, the AION V. This three-way collaboration not only allows the AION V to capture the attention of younger audiences in a more boundary-breaking way, but also gives social media users a deeper and more memorable impression of the AION V through a playful and culturally relevant approach.